Company News
Announcements
October 29, 2024
First Patient Enrolled
BioPorto is excited to announce that the first patient in its US study of ProNephro AKI™ (NGAL) for adult use has been enrolled at Massachusetts General Hospital. Read More
Announcements
October 10, 2024
Principal Investigator and CRO Named for US Adult Clinical Study
Dr. Andrew Allegretti, MD, MSC of Massachusetts General Hospital, has been appointed PI for the adult cutoff study and ProPharma has been selected as the CRO. Read More
Announcements
April 10, 2024
BioPorto Appoints Chief Legal Officer
Gry Louise Husby Larsen was appointed Executive Vice President and Chief Legal Officer (CLO). Read More
PRESS RELEASE
April 4, 2024
BioPorto Announces 2023 Annual Results; Releases Annual Report
2023 revenue growth attributed to a 25% increase in NGAL product sales. See the Annual Report for BioPorto’s strategic objectives and detailed action plan for the next 3-5 years. Read More
Announcements
April 2, 2024
Peter Mørch Eriksen Appointed Permanent Group CEO
BioPorto announces Peter Mørch Eriksen as permanent Group CEO after serving as interim CEO since January 2024. Read More
PRESS RELEASE
December 7, 2023
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States
ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker cleared for pediatric use (aged 3 months through 21 years) in the US and is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI. Read More